Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, our influenza vaccine candidate, has unique characteristics that stimulate multiple arms of the immune system and offers the potential to stop infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is a next-generation intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine. By leveraging the complementary attributes of its proprietary technology platforms, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including both acute and chronic infections and cancer. Source
No articles found.
With 40 million infertile people worldwide, MedAnswers connects patients with mult...
With 40 million infertile people worldwide, Med...
At Delee, we aim to radically change the way cancer is detected, monitored and tre...
At Delee, we aim to radically change the way ca...
Health Journal is a leader and influencer in health publishing in Virginia, USA an...
Health Journal is a leader and influencer in he...
Catalyst is focused on developing novel medicines to address serious medical condi...
Catalyst is focused on developing novel medicin...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Vaxart is focused on developing oral recombinant protein vaccines administered usi...
Vaxart is focused on developing oral recombinan...
Over a century ago in Melbourne, Australia, we made a promise to save lives and pr...
Over a century ago in Melbourne, Australia, we ...
Join the National Investor Network and get the latest information with your interests in mind.